Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor, Inc. (XNCR) Q4 2022 Earnings Call Transcript
11:11pm, Thursday, 23'rd Feb 2023
Xencor, Inc. (NASDAQ:XNCR ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President and CEO
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Thursday, 23'rd Feb 2023
Xencor (XNCR) delivered earnings and revenue surprises of 75.90% and 8.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
03:00pm, Tuesday, 31'st Jan 2023 Benzinga
Upgrades
For Silvercorp Metals Inc (AMEX:SVM), Raymond James upgraded the previous rating of Market Perform to Outperform. Silvercorp Metals earned $0.04 in the second quarter, compared to $0.08 in th
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
03:00pm, Monday, 30'th Jan 2023 Benzinga
Upgrades
According to B of A Securities, the prior rating for Flowserve Corp (NYSE:FLS) was changed from Neutral to Buy. Flowserve earned $0.09 in the third quarter, compared to $0.29 in the year-ago
Why Shares of Zencor Rose This Week
07:33pm, Thursday, 26'th Jan 2023 The Motley Fool
The clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago.
Why Shares of Zencor Rose This Week
02:33pm, Thursday, 26'th Jan 2023
The clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago.
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 04'th Jan 2023
MONROVIA, Calif.--( BUSINESS WIRE )--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune di
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
03:05pm, Tuesday, 06'th Dec 2022 Benzinga
Upgrades
According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was changed from Hold to Buy. United Airlines Holdings earned $2.81 in the third quarter, compared
Does Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect?
02:55pm, Wednesday, 30'th Nov 2022 Zacks Investment Research
The consensus price target hints at a 69.3% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
05:00pm, Friday, 25'th Nov 2022 Zacks Investment Research
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
01:33pm, Friday, 25'th Nov 2022
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?
02:55pm, Thursday, 10'th Nov 2022 Zacks Investment Research
The mean of analysts' price targets for Xencor (XNCR) points to a 74.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Xencor, Inc. (XNCR) Q3 2022 Earnings Call Transcript
11:36pm, Monday, 07'th Nov 2022
Xencor, Inc. (NASDAQ:XNCR ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President & CEO Joh
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
10:25pm, Monday, 07'th Nov 2022 Zacks Investment Research
Xencor (XNCR) delivered earnings and revenue surprises of 28.57% and 78.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
Xencor (XNCR) delivered earnings and revenue surprises of 28.57% and 78.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
